Skip to main content

New hope treatment in familial hypercholesterolemia

New hope comes today for those with familial hypercholesterolemia (FH).

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL, "bad cholesterol"), in the blood and early cardiovascular disease.



Without treatment, the life expectancy of those with familial hypercholesterolemia can be reduced by approximately 15-30 years. However, in people with homozygous familial hypercholesterolemia, life expectancy may only be 20 years or less.

Homologous chromosomes come in pairs. One homologous chromosome is inherited from the mother; the other is inherited from the father.  Homozygous refers to a gene that has identical alleles on both homologous chromosomes.   This is why the homozygous condition is particularly rare and can be more severe.

HoFH is a rare and more severe form of familial hypercholesterolemia (FH), an inherited condition characterized by very high levels of LDL-C and premature cardiovascular disease.

Inheriting FH- causing mutations from both parents results in HoFH in the child. HoFH is an extremely severe condition and is often associated with aggressive and markedly premature heart disease, including coronary artery disease and aortic valve disease. 

Children and teenagers with HoFH may have heart attacks or angina requiring the insertion of coronary stents or heart bypass surgery.

A new study shows that adding Praluent® (alirocumab) significantly reduced cholesterol levels by 35.6 per cent, compared to other lipid-lowering therapies alone, in patients with homozygous familial hypercholesterolemia.

The results of the placebo-controlled trial were presented at the joint meeting of the American College of Cardiology (ACC.20) together with the World Congress of Cardiology (WCC) Scientific Sessions.

Results showed treatment with Praluent significantly reduced other lipoprotein and lipid measures associated with elevated cardiovascular risk, including apolipoprotein B [29.8 percent (p<0.0001)], total cholesterol [26.5 percent (p<0.0001)], non-high-density lipoprotein cholesterol (HDL-C) [32.9 percent (p<0.0001)] and lipoprotein(a) [28.4 percent (p<0.0001)] versus placebo.

Lead investigator Dr Dirk Blom says,

“These results demonstrate a statistically significant and clinically-meaningful reduction in LDL-C levels after 12 weeks and have the potential to expand treatment options for very high-risk patients with this serious condition.”



Labels:

Comments

Post a Comment

Popular posts from this blog

Ian Duncan-Smith says he wants to make those on benefits 'better people'!

By any account, the government's austerity strategy is utilitarian. It justifies its approach by the presumed potential ends. It's objective is to cut the deficit, but it has also adopted another objective which is specifically targeted. It seeks to drive people off benefits and 'back to work'.  The two together are toxic to the poorest in society. Those least able to cope are the most affected by the cuts in benefits and the loss of services. It is the coupling of these two strategic aims that make their policies ethically questionable. For, by combining the two, slashing the value of benefits to make budget savings while also changing the benefits system, the highest burden falls on a specific group, those dependent on benefits. For the greater good of the majority, a minority group, those on benefits, are being sacrificed; sacrificed on the altar of austerity. And they are being sacrificed in part so that others may be spared. Utilitarian ethics considers the ba...
7 comments
Read more

Ethical considerations of a National DNA database.

Plans for a national DNA database   will be revealed by the Prime Minister this week. This is the same proposal the Tories and Liberal Democrats opposed when presented by the Blair government because they argued it posed  a threat to civil liberties. This time it is expected to offer an 'opt-out' clause for those who do not wish their data to be stored; exactly how this would operate isn't yet clear. But does it matter and does it really pose a threat to civil liberties? When it comes to biology and ethics we tend to have a distorted view of DNA and genetics. This is for two reasons. The first is that it is thought that our genome somehow represents the individual as a code that then gets translated. This is biologically speaking wrong. DNA is a template and part of the machinery for making proteins. It isn't a code in anything like the sense of being a 'blueprint' or 'book of life'.  Although these metaphors are used often they are just that, metapho...
2 comments
Read more

The unethical language of 'welfare dependency'

It is unethical to stigmatise people without foundation. Creating a stereotype, a generalised brand, in order to  demonize a group regardless of the individual and without regard for the potential harm it may do is unfair and prejudicial. It is one reason, and a major one, why racism is unethical; it fails to give a fair consideration of interest to a group of people simply because they are branded in this way. They are not worthy of equal consideration because they are different.  It seeks also to influence the attitudes of others to those stereotyped. If I said 'the Irish are lazy'; you would rightly respond that this is a ridiculous and unfounded stereotype. It brands all Irish on the basis of a prejudice. It is harmful certainly; but it is worse if I intend it to be harmful. If I intend to influence the attitude of others. And so it is with 'the unemployed'. All I need do is substitute 'work-shy' and use it in an injudicious way; to imply that it applies to...
2 comments
Read more